Virtu KCG Holdings’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Virtu KCG Holdings’s Portfolio MBVX Stock Details MBVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-5,264	Closed	-$53K	–	4082
2016 Q4	$53K	Sell	5,264 -17,558	-77%	-$201K	﹤0.01%	3081
2016 Q3	$290K	Buy	+22,822	New	+$344K	0.01%	1962

Other funds holding MBVX

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DRD

Dennis R. Delaney $282M AUM 16.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtu KCG Holdings's MBVX Position: Q1 2017 in Review

Virtu KCG Holdings sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q1 2017, closing a stake of 5,264 shares — an estimated $53K sold.

Virtu KCG Holdings first reported a position in MBVX in Q3 2016 and held it in 2 quarters. The position peaked at $290K in Q3 2016. 8 funds tracked by Wall St. Rank hold MBVX as of Q1 2017.

Virtu KCG Holdings reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q1 2017 after selling out during the quarter.
Virtu KCG Holdings sold 5,264 MABVAX THERAPEUTICS HLDGS INC shares in Q1 2017, an estimated $53K.
Virtu KCG Holdings first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q3 2016 and held it in 2 quarters.
Virtu KCG Holdings's MABVAX THERAPEUTICS HLDGS INC position peaked at $290K in Q3 2016.
8 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q1 2017.

Based on Virtu KCG Holdings's 13F filing for Q1 2017, filed 12 May 2017.